594 results match your criteria Current Hematologic Malignancy Reports[Journal]


Relapsed T Cell ALL: Current Approaches and New Directions.

Curr Hematol Malig Rep 2019 Mar 18. Epub 2019 Mar 18.

Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.

Purpose Of Review: Patients with relapsed T cell acute lymphoblastic leukemia (T-ALL) have limited therapeutic options and a poor prognosis. Although a variety of salvage chemotherapy regimens may be used, response rates are unsatisfactory. This article summarizes current approaches and promising emerging strategies for the treatment of relapsed T-ALL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00501-3DOI Listing
March 2019
1 Read

Recent Advances in Adult Acute Lymphoblastic Leukemia.

Curr Hematol Malig Rep 2019 Mar 16. Epub 2019 Mar 16.

Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX, 77030, USA.

Purpose Of Review: This article reviews the recent advances in the pathophysiology and management of acute lymphoblastic leukemia (ALL) in adults.

Recent Findings: Addition of rituximab to standard chemotherapy improves survival in the frontline treatment of B cell ALL, and measurable residual disease (MRD) is the most important prognostic factor. Tyrosine kinase inhibitors (TKI), particularly ponatinib, in combination with Hyper-CVAD significantly improve outcomes in Ph + ALL challenging the benefit of allogeneic stem cell transplant in first line for these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00503-1DOI Listing
March 2019
3 Reads

Development and Significance of Mouse Models in Lymphoma Research.

Curr Hematol Malig Rep 2019 Mar 8. Epub 2019 Mar 8.

College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.

Purpose Of Review: Animal models have played an indispensable role in interpreting cancer gene functions, pathogenesis of disease, and in the development of innovative therapeutic approaches targeting aberrant biological pathways in human cancers.

Recent Findings: These models have guided the therapeutic targeting of cancer-causing mutations and paved the way for assessing anti-cancer drug responses and the preclinical development of immunotherapies. The mammalian models of cancer utilize genetically edited or transplanted mice that develop fairly accurate disease histopathology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00504-0DOI Listing
March 2019
1 Read

Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists.

Curr Hematol Malig Rep 2019 Mar 4. Epub 2019 Mar 4.

Blood and Marrow Transplantation, Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Purpose Of Review: We summarise the current development of autologous haematopoietic stem cell transplantation (AHSCT) in treating multiple sclerosis (MS) and discuss future directions for the general neurologist, transplant haematologist and oncologist.

Recent Findings: AHSCT was initially performed to treat MS over 20 years ago. Over recent years, the evidence base has grown, especially in relapsing-remitting MS (RRMS), with significant improvements in safety and efficacy through better patient selection, choice of transplant technique and increase in centre experience. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00505-zDOI Listing

Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population.

Curr Hematol Malig Rep 2019 Feb 28. Epub 2019 Feb 28.

Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

Purpose Of Review: Approximately one half of the patient-population in multiple myeloma (MM) is > 70 years at diagnosis. Despite notable strides in the management and improved survival, MM remains incurable, with an increasing proportion of elderly patients comprising the relapsed-refractory cohort.

Recent Findings: The arbitrary age cutoff at 65 years to define the elderly patient-population has evolved to a more nuanced categorization, incorporating a comprehensive assessment for determining frailty prior to commencing treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00500-4DOI Listing
February 2019
1 Read
2.286 Impact Factor

The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders.

Curr Hematol Malig Rep 2019 Feb;14(1):11-21

Dana-Farber Cancer Institute, Boston, MA, USA.

Purpose Of The Review: Lymphomas represent clinically and molecularly heterogeneous diseases with variable presentations, treatment algorithms, and outcomes. As treatment options continue to expand, more sophisticated prognostic and predictive biomarkers are needed to guide personalized treatment approaches.

Recent Findings: Liquid biopsies, in which the sequencing of circulating tumor DNA (ctDNA) in peripheral blood serves as a surrogate for a tumor biopsy, are now being studied across cancer subtypes, including in lymphoid malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-0493-yDOI Listing
February 2019
1 Read

Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia.

Curr Hematol Malig Rep 2019 Feb 26. Epub 2019 Feb 26.

Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, Piazza Sant'Onofrio, 4, 00165, Rome, Italy.

Purpose Of Review: The remarkable improvement in the prognosis of children with acute lymphoblastic leukemia (ALL) has been mainly achieved through the administration of risk-adapted therapy, including allogeneic hematopoietic stem cell transplantation (HSCT). This paper reviews the current indications to HSCT in ALL children, as well as the type of donor and conditioning regimens commonly used. Finally, it will focus on future challenges in immunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00502-2DOI Listing
February 2019
3 Reads

Solitary Plasmacytoma: a Review of Diagnosis and Management.

Curr Hematol Malig Rep 2019 Feb 20. Epub 2019 Feb 20.

Scripps Clinic, 10666 N Torrey Pines Road, MS312, La Jolla, CA, 92037, USA.

Purpose Of Review: Solitary plasmacytoma is a rare plasma cell dyscrasia, classified as solitary bone plasmacytoma or solitary extramedullary plasmacytoma. These entities are diagnosed by demonstrating infiltration of a monoclonal plasma cell population in a single bone lesion or presence of plasma cells involving a soft tissue mass, respectively. Both diseases represent a single localized process without significant plasma cell infiltration into the bone marrow or evidence of end organ damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00499-8DOI Listing
February 2019

Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Curr Hematol Malig Rep 2019 Feb;14(1):39-46

Department of Internal Medicine, University of Nebraska Medical Center, 986840 Nebraska Medical Center, Omaha, NE, 68198, USA.

Purpose Of Review: The ability to detect minimal residual disease (MRD) in myeloma has improved due to advances in flow cytometry and sequencing methodologies. Here, we evaluate recent clinical trial data and explore the current and future roles of MRD assessment in the context of clinical trial design and clinical practice.

Recent Findings: A review of recent phase III studies reveals that achievement of MRD negativity is associated with improved progression-free survival (PFS) and/or overall survival (OS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-0497-7DOI Listing
February 2019

Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.

Curr Hematol Malig Rep 2019 Feb;14(1):47-55

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Purpose Of Review: We describe the significant technological leap from bench to bedside that was achieved through a strong academic-industry collaboration between dedicated clinicians and researchers at the University of Pennsylvania, the Children's Hospital of Philadelphia, and Novartis to commercialize the chimeric antigen receptor T cell (CAR-T) therapy tisagenlecleucel (CTL019; Kymriah®; Novartis Pharma AG, Basel, Switzerland).

Recent Findings: Tisagenlecleucel was the first CAR-T therapy and the first gene therapy to receive US Food and Drug Administration approval in 2017, with an initial indication for pediatric and young adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia, followed by approval in May 2018 for a second indication in adult patients with r/r diffuse large B cell lymphoma. Subsequent approvals in the European Union, Switzerland, and Canada soon followed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-0498-6DOI Listing
February 2019
17 Reads

Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?

Authors:
Myo Htut

Curr Hematol Malig Rep 2019 Feb;14(1):1-10

Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA, 91010, USA.

Purpose Of Review: The treatment landscape for multiple myeloma has evolved rapidly with the availability of multiple new drugs; however, although patient survival has improved, the disease remains incurable. Multiple myeloma is characterized by the unregulated growth of malignant plasma cells accompanied by immune dysfunction as well as disrupted immune surveillance mechanisms. Here, we analyze clinical modalities, with a focus on monoclonal antibodies and adoptive cellular therapy that enhance patients' immune systems and overcome these defects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-0492-zDOI Listing
February 2019
1 Read

Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?

Curr Hematol Malig Rep 2019 Feb;14(1):31-38

Department of Medicine, Blood and Marrow Transplant Center, Transplant and Cellular Therapy Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Purpose Of Review: While the traditional gold standard for demonstrating clinical benefit of a therapy has been to show prolongation of overall survival (OS), there are multiple factors which can hinder the use of OS as a primary endpoint in randomized clinical trials (RCTs). Here, we analyze recent myeloma RCTs and evaluate the issues relevant to current and future myeloma RCT design.

Recent Findings: A review of recent phase III RCTs that led to approval of new agents/combinations reveals that none were designed with OS as the primary endpoint, but instead utilized time to progression (TTP) or progression-free survival (PFS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-0495-9DOI Listing
February 2019
2 Reads

Treatment-Free Remission in CML: the US Perspective.

Curr Hematol Malig Rep 2019 Feb;14(1):56-61

Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

Purpose Of Review: Chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI) have near-normal life expectancy. However, lifelong TKI therapy is associated with reduced quality of life and significant economic burden. Currently, the management of CML is shifting from continuous TKI therapy towards the goal of TKI cessation which is discussed in this review. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-019-0496-8
Publisher Site
http://dx.doi.org/10.1007/s11899-019-0496-8DOI Listing
February 2019
10 Reads

Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?

Authors:
Bronwen E Shaw

Curr Hematol Malig Rep 2019 Feb;14(1):22-30

CIBMTR (Center for International Blood and Marrow Transplant Research)/Froedtert, Department of Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Suite C5500, Milwaukee, WI, 53226, USA.

Purpose Of Review: Graft versus host disease (GVHD) is a common complication following hematopoietic cell transplant and is associated with a high symptom burden, reduced functional status, and impaired quality of life (QOL). QOL is best assessed by patient-reported outcomes (PRO). Numerous clinical trials for the prevention and treatment of GVHD are available. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-019-0494-x
Publisher Site
http://dx.doi.org/10.1007/s11899-019-0494-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408224PMC
February 2019
18 Reads

Targeted Therapies in CLL: Monotherapy Versus Combination Approaches.

Curr Hematol Malig Rep 2018 Dec;13(6):525-533

Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 E. Duarte Rd., Duarte, CA, 91010, USA.

Purpose Of Review: While chemoimmunotherapy has improved outcomes in chronic lymphocytic leukemia (CLL), it is not curative, has significant relapse rates, and is not always well tolerated. Recently, novel targeted therapies have been developed to increase response rates and reduce toxicity, especially in high-risk disease. Current goals of CLL therapies are to produce deep and durable, especially minimal residual disease (MRD)-negative, remissions so as to allow patients to ultimately discontinue treatment for a while. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0481-7
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0481-7DOI Listing
December 2018
16 Reads

Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.

Curr Hematol Malig Rep 2018 Dec;13(6):455-466

Department of Pathology, University of Texas Southwestern Medical Center, BioCenter EB3.234, 2330 Inwood Road, Dallas, TX, 75390-9317, USA.

Purpose Of Review: Minimal or measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) is an independent prognostic indicator in acute leukemia. However, the predictive value of MFC MRD is affected by technical challenges, interpretive complexities, and inadequate standardization, particularly in acute myeloid leukemia (AML). Here, we critically review the methodological principles of the MFC MRD assay and discuss clinical implications of MRD. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0479-1
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0479-1DOI Listing
December 2018
17 Reads

Correction to: Strategies for Predicting Response to Checkpoint Inhibitors.

Curr Hematol Malig Rep 2019 Feb;14(1):62

Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0488-0
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0488-0DOI Listing
February 2019
10 Reads

Chronic Myeloid Leukemia: Beyond BCR-ABL1.

Curr Hematol Malig Rep 2018 Dec;13(6):435-445

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0072, Houston, TX, 77030, USA.

Purpose Of Review: In this review, we emphasize up-to-date practical cytogenetic and molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on tyrosine kinase inhibitor (TKI) resistance and treatment response monitoring of CML.

Recent Findings: The introduction of TKIs has changed the natural course of CML and markedly improved patient survival. Over the past decades, many research efforts were devoted to elucidating the leukemogenic mechanisms of BCR-ABL1 and developing novel TKIs. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0474-6
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0474-6DOI Listing
December 2018
17 Reads

Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.

Curr Hematol Malig Rep 2018 Dec;13(6):534-542

Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, 1950 Circle of Hope, Salt Lake City, UT, 84112, USA.

Purpose Of Review: This article will review the use of anti-CD19 CAR-T therapy used in relapsed/refractory diffuse large B cell lymphoma.

Recent Findings: The clinical outcomes, safety analysis, and other relevant considerations will be discussed with an emphasis on the most recently published data regarding the ZUMA-1, JULIET, and TRANSCEND NHL-001 trials. Anti-CD19 CAR-T therapy is an exciting new therapy now approved and available to patients with relapsed/refractory diffuse large B cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0482-6DOI Listing
December 2018
2 Reads

Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.

Curr Hematol Malig Rep 2018 Dec;13(6):555-569

Columbia University Medical Center, New York, NY, 10032, USA.

Purpose Of Review: This review is about the antibody-drug conjugate (ADC), a form of drug delivery consisting of a monoclonal antibody, linker, and cytotoxic payload. We summarize the history of ADC development, highlighting the three FDA-approved ADCs currently available.

Recent Findings: Gemtuzumab ozogamicin is a CD33-targeted ADC linked to calicheamicin. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0485-3
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0485-3DOI Listing
December 2018
4 Reads

Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.

Curr Hematol Malig Rep 2018 Dec;13(6):588-595

Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 443, New York, NY, 10022, USA.

Purpose Of Review: Although BCR-ABL1-negative myeloproliferative neoplasms (MPN) are chronic, clonal hematopoietic stem cell (HSC) disorders marked by proliferation of one or more myeloid lineages, a substantial proportion of patients transform to acute myeloid leukemia. Leukemic transformation (LT) from a pre-existing MPN carries a dismal prognosis. Here, we review recent genetic, biological, and clinical data regarding LT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0491-5DOI Listing
December 2018
3 Reads

Blastic Plasmacytoid Dendritic Cell Neoplasm.

Authors:
Joseph D Khoury

Curr Hematol Malig Rep 2018 Dec;13(6):477-483

Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, MS-072, Houston, TX, 77030, USA.

Purpose Of Review: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood.

Recent Findings: TCF4 is a master regulator that drives donwstream transcriptional programs in BPDCN. In turn, TCF4 activity is dependent on the bromodomain and extra-terminal domain (BET) protein BRD4 whose inhibition provides a promising therapeutic vulnerability. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0489-z
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0489-zDOI Listing
December 2018
3 Reads

Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Curr Hematol Malig Rep 2018 Dec;13(6):516-524

Medical Oncology and Cancer Immunology, Epworth Healthcare, 140 Clarendon Street, East Melbourne, Victoria, 3002, Australia.

Purpose Of Review: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently recognised malignancy of T lymphocytes exclusively associated with textured breast implants. This review aims to evaluate existing theories regarding the epidemiology, pathogenesis, clinical evaluation and management of the disease.

Recent Findings: The true incidence of BIA-ALCL is difficult to define. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0478-2DOI Listing
December 2018
1 Read

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community.

Curr Hematol Malig Rep 2018 Dec;13(6):581-587

Dana-Farber Cancer Institute, Boston, MA, USA.

Purpose Of Review: Engagement on social media for professional, healthcare-related communication is rapidly rising around the world. We aimed to better understand the dynamics of a rare disease Twitter hashtag community.

Recent Findings: Twitter has served as a platform for academic discussion, a method for knowledge dissemination directly from medical meetings, and a venue for patient caregiver and support groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0490-6DOI Listing
December 2018
1 Read

Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.

Curr Hematol Malig Rep 2018 Dec;13(6):543-554

Department of Hematologic Malignancies and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

Purpose Of The Review: The ligation of PD-1 with PD-L1 activates a critical immune checkpoint leading to T cell dysfunction, exhaustion, and tolerance. Anti-PD-1 or anti-PD-L1 monoclonal antibodies can reverse the immune checkpoint, releasing the brake on T cell responses. We provide a comprehensive review of the literature on the activity of checkpoint inhibitors in lymphoma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0484-4
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0484-4DOI Listing
December 2018
32 Reads

Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria.

Curr Hematol Malig Rep 2018 Dec;13(6):467-476

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, MS-072, Houston, TX, 77030, USA.

Purpose Of Review: This review provides a comprehensive update of myelodysplastic syndromes (MDS) and their diagnostic criteria, with emphasis on novel concepts and state-of-the-art laboratory workup, including multiparameter/multicolor flow cytometry, chromosome analysis, and mutation profiling.

Recent Findings: Recent advances in genetics and molecular technologies have provided unprecedented insights into the pathogenic mechanisms and genomic landscape of MDS and its precursor lesions. This has resulted in revised diagnostic criteria in the World Health Organization (WHO) classification and proposed new terminology for early lesions such as clonal hematopoiesis of indeterminate potential (CHIP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0483-5DOI Listing
December 2018
2 Reads
2.290 Impact Factor

Social Media and Hematopoietic Cell Transplantation: a Review of Online Resources and Communities.

Curr Hematol Malig Rep 2018 Dec;13(6):576-580

Blood & Marrow Transplant Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, CA-60, Cleveland, OH, 44195, USA.

Purpose Of Review: Social media has dramatically changed the access and exchange of information in healthcare and beyond. A variety of platforms and resources exist allowing blood and marrow transplant providers, researchers, and patients to interact. We review the adoption of social media by the transplantation community. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0487-1DOI Listing
December 2018
1 Read

Novel Immunotherapies for T Cell Lymphoma and Leukemia.

Curr Hematol Malig Rep 2018 Dec;13(6):494-506

Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Purpose Of Review: Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are characterized by poor clinical outcomes. This review describes the rational and preliminary results of immunotherapy for patients with T cell lymphoma and leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0480-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295363PMC
December 2018
1 Read
2.290 Impact Factor

Recent Updates on Chronic Myelomonocytic Leukemia.

Curr Hematol Malig Rep 2018 Dec;13(6):446-454

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0072, Houston, TX, 77030, USA.

Purpose Of Review: The goal of this review is to provide a practical and comprehensive update on changes in the classification of chronic myelomonocytic leukemia (CMML) and a summary of the most recent developments in our understanding of its genomic landscape, prognostic models, and therapeutic approaches.

Recent Findings: The 2017 revision of the World Health Organization (WHO) classification includes substantial changes to the subclassification CMML. The clinical utility of the newly revised subclassification scheme is discussed. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0475-5
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0475-5DOI Listing
December 2018
15 Reads

Online and Social Media Resources for Patients with MDS.

Curr Hematol Malig Rep 2018 Dec;13(6):570-575

Department of Hematology and Medical Oncology, Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University, Taussig Cancer Institute, Desk R35 9500 Euclid Ave., Cleveland, OH, 44195, USA.

Purpose Of Review: The number of online resources for patients with MDS is exponentially increasing; this is in large part due to the advent of social media which has introduced multiple avenues for information exchange and communication. Whether this information is targeted towards the patient population or not, the wealth of information online represents a new era of patient engagement in their health care. This review aims to highlight the different online resources being used in the field of MDS. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0486-2
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0486-2DOI Listing
December 2018
12 Reads

Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy.

Curr Hematol Malig Rep 2018 Dec;13(6):484-493

Department of Medicine, University of Washington, 1100 Fairview AVE N, Mailstop # D5-100, Seattle, WA, 98109, USA.

Purpose Of Review: Cellular therapy using T cells modified to express chimeric antigen receptors (CAR-T cells) has had striking success in patients that have failed previous treatment for CD19 B cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), or acute lymphoblastic leukemia (ALL). Curative therapy for this group of diseases has previously been limited to allogeneic hematopoietic cell transplantation HCT (alloHCT). The recent results of CAR-T cell therapy raise the question of how best to integrate CAR-T cell therapy and alloHCT in the care of these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0476-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333424PMC
December 2018
4 Reads

Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.

Curr Hematol Malig Rep 2018 Dec;13(6):417-425

Division of Oncology, Washington University School of Medicine, 660 S. Euclid Ave, CB 8007, St. Louis, MO, 63110, USA.

Purpose Of Review: Bispecific antibodies combine antigen recognition sites from two or more antibodies into a single construct allowing simultaneous binding to multiple targets. Bispecific antibodies exist which can redirect immune effector cells against acute myeloid leukemia (AML) targets. This review will highlight the progress to date and the challenges in developing bispecific antibodies for the treatment of AML. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0472-8
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0472-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295344PMC
December 2018
3 Reads

Leveraging Hypomethylating Agents for Better MDS Therapy.

Curr Hematol Malig Rep 2018 Dec;13(6):507-515

Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 90 SW 3rd Street #2210, Miami, FL, 33130, USA.

Purpose Of Review: Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond, most responses are not durable, and the only hope for a cure is allogeneic stem cell transplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0477-3DOI Listing
December 2018
3 Reads

Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies.

Curr Hematol Malig Rep 2018 Dec;13(6):426-434

Section of Hematology/Oncology, Department of Medicine, The University of Chicago Comprehensive Cancer Center, The University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL, 60637, USA.

Purpose Of Review: To review the diagnosis of individuals with hereditary hematopoietic malignancies (HHMs) that predispose to myelodysplastic syndrome and acute myeloid leukemia, barriers to HHM diagnosis, and unaddressed questions and controversies within the HHM field.

Recent Findings: Pathogenic germline mutations in approximately a dozen genes predispose to HHMs, and many more genes are likely to be involved. Many of these HHM genes have only been identified recently. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0473-7DOI Listing
December 2018
4 Reads

Strategies for Predicting Response to Checkpoint Inhibitors.

Curr Hematol Malig Rep 2018 10;13(5):383-395

Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

Purpose Of Review: Despite the clinical successes of immune checkpoint blockade across multiple tumor types, many patients do not respond to these therapies or become resistant after an initial response. This underscores the need to improve our understanding of the molecular determinants of response to guide more personalized and rational utilization of these therapies. Here, we describe available biomarkers of checkpoint blockade activity by classifying them into four major categories: tumor-intrinsic, immune microenvironmental, host-related, and dynamic factors. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0471-9
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0471-9DOI Listing
October 2018
21 Reads

Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.

Curr Hematol Malig Rep 2018 10;13(5):407-416

Division of Hematology, Stanford Cancer Institute / Stanford University School of Medicine, 875 Blake Wilbur Drive, Room 2324, Stanford, CA, 94305-5821, USA.

Purpose Of Review: We discuss recent developments in the treatment of advanced systemic mastocytosis (advSM) with inhibitors of the KIT receptor tyrosine kinase.

Recent Findings: advSM is a heterogeneous group of neoplasms of poor prognosis characterized by the accumulation of neoplastic mast cells. The canonical KIT D816V mutation is present in approximately 90% of SM patients, and its detection is critical for both diagnosis and therapeutic decision-making. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0469-3DOI Listing
October 2018
27 Reads

Updates on Circulating Tumor DNA Assessment in Lymphoma.

Curr Hematol Malig Rep 2018 10;13(5):348-355

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA.

Purpose Of Review: The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications.

Recent Findings: Recent studies have demonstrated the use of ctDNA assessment across many lymphoma subtypes including diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin lymphoma, and T-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0468-4DOI Listing
October 2018
8 Reads

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.

Curr Hematol Malig Rep 2018 10;13(5):396-406

Division of Pediatric Hematology/Oncology, Department of Pediatrics, Department of Internal Medicine, University of Virginia, PO Box 800386, Charlottesville, VA, 22908, USA.

Purpose Of Review: Genetically engineered T cells expressing a chimeric antigen receptor (CAR-T) targeting specific antigens present on acute lymphoblastic leukemia (ALL) blasts have generated promising results in children and adults with relapsed and refractory disease. We review the current evidence for CAR-T cell therapy in ALL, associated toxicities, and efforts to improve durable response to therapy.

Recent Findings: CD19-directed CAR-T cells have recently been approved by the FDA for use in children and young adults with ALL and in adults with diffuse large B cell lymphoma (DLBCL) in the relapsed/refractory setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0470-xDOI Listing
October 2018
10 Reads

Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma.

Curr Hematol Malig Rep 2018 10;13(5):356-368

Division of Hematology/Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

Purpose Of Review: Diffuse large B cell lymphoma (DLBCL) remains the most common non-Hodgkin lymphoma (NHL) in developed countries. Up to 30-40% of patients experience either refractory or relapsed disease following receipt of front-line chemoimmunotherapy, and the majority of these patients will not be cured following receipt of subsequent therapy.

Recent Findings: Small-molecule inhibitors (SMIs) are an attractive class of therapeutics for patients with chemorefractory DLBCL, and early-phase studies with these agents have typically demonstrated prolonged periods of disease control in responding patients without significant toxicity. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0467-5
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0467-5DOI Listing
October 2018
22 Reads

Emerging EZH2 Inhibitors and Their Application in Lymphoma.

Curr Hematol Malig Rep 2018 10;13(5):369-382

Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, 51 W 51st Street, Suite 200, New York, NY, 10019, USA.

Purpose Of Review: Enhancer of Zeste Homolog 2 (EZH2) is histone methyltransferase and catalyzes the methylation of histone 3 lysine 27, a mark of transcriptional repression. Various studies have elucidated the complex role of EZH2 in both normal biology and tumorigenesis. Here, we critically review the emerging role of EZH2 in malignancies, the development of small molecule inhibitors of EZH2, and their application in lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0466-6DOI Listing
October 2018
3 Reads

Novel Therapies in Acute Lymphoblastic Leukemia.

Curr Hematol Malig Rep 2018 08;13(4):289-299

Taussig Cancer Center, Cleveland Clinic, 10201 Carnegie Avenue, Desk CA60, Cleveland, OH, 44195, USA.

Purpose Of Review: Treatment options for patients with acute lymphoblastic leukemia (ALL) beyond standard chemotherapy have grown significantly in recent years. In this review, we highlight new targeted therapies in ALL, with an emphasis on immunotherapy.

Recent Findings: Major advances include antibody-based therapies, such as naked monoclonal antibodies, antibody-drug conjugates and bispecific T cell engaging (BiTE) antibodies, as well as adoptive cellular therapies such as chimeric antigen receptor (CAR) T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0457-7DOI Listing
August 2018
1 Read

Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia.

Curr Hematol Malig Rep 2018 10;13(5):341-347

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Purpose Of Review: To evaluate established prognostic models in chronic myelomonocytic leukemia (CMML) and describe the challenges associated with their application in clinical practice.

Recent Findings: CMML is a clonal hematopoietic stem cell disorder with heterogeneous clinical and molecular features. Outcomes of CMML patients can vary from indolent disease with expected survival measured in years versus proliferative subtypes with rapid progression to acute myeloid leukemia and survival measured in months. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0465-7
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0465-7DOI Listing
October 2018
22 Reads

Adult T Cell Leukemia-Lymphoma (ATL): State of the Art.

Curr Hematol Malig Rep 2018 08;13(4):300-307

Department of Medicine, New York Presbyterian Queens, Flushing, NY, 11355, USA.

Purpose Of Review: ATL is a rare and highly aggressive T cell malignancy caused by HTLV-1. We will review the state of the art of ATL epidemiology, pathogenesis, diagnosis, and treatment.

Recent Findings: Because of population migration, cases of ATL in non-HTLV-1 endemic countries including North America and Europe are increasingly recognized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0458-6DOI Listing
August 2018
22 Reads

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward.

Curr Hematol Malig Rep 2018 08;13(4):329-340

Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Mail Code L586, Portland, OR, 97239, USA.

Purpose Of Review: Outcomes for older adults with acute lymphoblastic leukemia (ALL) remain poor, and allogeneic hematopoietic stem cell transplant (HSCT) remains a potentially curative modality. However, benefits are offset by high rates of non-relapse mortality (NRM) in patients undergoing myeloablative conditioning (MAC) regimens. Reduced intensity conditioning (RIC) regimens can extend this therapy to adults who are unfit for MAC, although at the cost of higher relapse rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0462-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097057PMC
August 2018
1 Read

Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty.

Curr Hematol Malig Rep 2018 08;13(4):237-243

Division of Hematology and Medical Oncology, Mayo Clinic, 5881 E. Mayo Blvd, Phoenix, AZ, 85054, USA.

Purpose Of Review: Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices.

Recent Findings: The cost of therapy for CLL has increased substantially since the introduction of oral therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0461-yDOI Listing
August 2018
18 Reads
2.290 Impact Factor

Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.

Curr Hematol Malig Rep 2018 08;13(4):256-264

Division of Hematology, University of Colorado School of Medicine, 1665 Aurora Court, Mail Stop F754, Aurora, CO, 80045, USA.

Purpose Of Review: Apoptosis results from the interaction between pro- and anti-apoptotic proteins, mediated by BCL-2 homology 3 (BH3) proteins. B cell lymphoma-2 (BCL-2) is an inhibitor of apoptosis which stabilizes the mitochondria, resulting in the prevention of activation of the pro-apoptotic proteins. In addition, BCL-2 is overexpressed in the leukemic stem cell (LSC) population, and its inhibition may lead to selective LSC eradication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0464-8DOI Listing
August 2018
23 Reads
2.290 Impact Factor

Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review.

Curr Hematol Malig Rep 2018 08;13(4):318-328

Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 68198-6842, USA.

Purpose Of Review: Peripheral T cell lymphoma (PTCL) is a heterogeneous group of lymphoproliferative neoplasms, with at least 29 distinct entities described in current WHO classification. Using present diagnostic approaches, more than a third of PTCL cases cannot be classified, hence designated as PTCL-not otherwise specified (PTCL-NOS). Herein, we summarize the current genomic findings and their role in the molecular pathogenesis in different PTCL entities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0460-zDOI Listing
August 2018
15 Reads

Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Curr Hematol Malig Rep 2018 08;13(4):275-288

Departments of Pathology & Dermatology, University of Virginia, 415 Lane Road, Hospital Expansion Bldg Room 3024, Charlottesville, VA, 22908, USA.

Purpose Of Review: Acute lymphoblastic leukemias (ALL) are malignant disorders of immature B or T cells that occur characteristically in children, usually under the age of 6 (75%). Approximately 6000 new cases of ALL are diagnosed each year in the USA, 80-85% of which represent B-ALL forms. Most presentations of B-ALL are leukemic, whereas T-ALL presents with a mediastinal mass, with or without leukemic involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0456-8DOI Listing
August 2018
4 Reads

Novel Approaches for the Management of AL Amyloidosis.

Curr Hematol Malig Rep 2018 06;13(3):212-219

Winship Cancer Institute, Emory University, 1365C Clifton Road, Atlanta, GA, 30322, USA.

Purpose Of Review: Light-chain-associated (AL) amyloidosis is a rare disease with a poor prognosis. However, we have made recent strides in more accurate diagnosis and effective treatment. Here, we discuss the most recent updates and advancements during the past year in the diagnosis, prognostication, and management of AL amyloidosis both in the upfront and relapsed setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0450-1DOI Listing
June 2018
21 Reads

Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia.

Curr Hematol Malig Rep 2018 08;13(4):265-274

Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.

Purpose Of Review: This article provides an overview of the current knowledge regarding the biology and treatment of T cell acute lymphoblastic leukemia (T-ALL) and highlights the most recent findings in this field over the past 5 years.

Recent Findings: Remarkable progress has been made in the genomic landscape of T-ALL over the past few years. The discovery of activating mutations of NOTCH1 and FBXW7 in a majority of patients has been a seminal observation, with several early phase clinical trials currently exploring these as potential therapeutic targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-018-0455-9DOI Listing
August 2018
31 Reads